News

US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the 13 Biotech Stocks with Huge Upside Potential. It declared that the U.S ...
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce ...
Robert W. Baird Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
In a report released today, Joel Beatty from Robert W. Baird maintained a Buy rating on Axsome Therapeutics ( AXSM – Research Report ), with a price target of $157.00. The company’s shares opened ...
US appeals court upholds Acadia’s patent for Parkinson’s drug in MSN Labs case
US Court of Appeals upholds Acadia Pharmaceuticals' patent for Nuplazid, securing protection against generic competition ...
EconoTimes4d
Acadia Secures Nuplazid Patent Protection Through 2038 After Appeals Court Ruling
Acadia Pharmaceuticals (NASDAQ: ACAD) announced that the U.S. Court of Appeals has upheld the validity of its patent for ...
US appeals court confirms patent validity of Acadia's Parkinson's drug
Acadia Pharmaceuticals said on Monday that the U.S. Court of Appeals has confirmed the validity of its patent for Nuplazid, ...
Acadia Pharmaceuticals Gets Another Court Win for Parkinson's Treatment
Acadia Pharmaceuticals has scored a second court win in less than a month that protects patents for its Parkinson's Disease treatment Nuplazid. The biopharmaceutical company said Monday that a federal ...